51 – 60 of 96
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain
(
- Contribution to journal › Scientific review
-
Mark
In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to l-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels
(
- Contribution to journal › Article
-
Mark
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
(
- Contribution to journal › Article
- 2011
-
Mark
Enriched environment downregulates macrophage migration inhibitory factor and increases parvalbumin in the brain following experimental stroke
(
- Contribution to journal › Article
-
Mark
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
(
- Contribution to journal › Article
-
Mark
Cleavage of the vesicular glutamate transporters under excitotoxic conditions
(
- Contribution to journal › Article
-
Mark
Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice.
(
- Contribution to journal › Article
-
Mark
Apoptosis-inducing factor mediates dopaminergic cell death in response to lps-induced inflammatory stimulus Evidence in Parkinson's disease patients.
(
- Contribution to journal › Article
- 2010
-
Mark
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
(
- Contribution to journal › Article
-
Mark
Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis.
(
- Contribution to journal › Article